Sichuan Goldstone Asia Pharmaceutical Inc. (SHE:300434)
China · Delayed Price · Currency is CNY 13.16
+0.75 (6.04%)
Oct 9, 2026, 2:25 PM CST
SHE:300434 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,287 | 4,130 | 3,314 | 4,443 | 5,468 | 4,363 | |
Market Cap Growth | 39.26% | 24.61% | -25.41% | -18.74% | 25.32% | 42.33% |
Enterprise Value | 4,935 | 3,880 | 2,833 | 3,779 | 5,197 | 4,148 |
Last Close Price | 12.41 | 10.19 | 8.12 | 10.72 | 13.20 | 10.53 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 30.69 | 31.38 | 36.12 | 35.21 | 24.99 | 65.63 |
PS Ratio | 4.81 | 3.98 | 3.01 | 3.68 | 4.40 | 4.14 |
PB Ratio | 1.89 | 1.61 | 1.34 | 1.83 | 2.37 | 2.02 |
P/TBV Ratio | 2.14 | 1.83 | 1.55 | 2.15 | 2.95 | 2.65 |
P/FCF Ratio | 63.98 | 38.13 | 38.89 | 52.25 | 20.33 | 85.50 |
P/OCF Ratio | 29.74 | 19.87 | 20.96 | 29.40 | 16.93 | 31.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.47 | 3.74 | 2.57 | 3.13 | 4.18 | 3.94 |
EV/EBITDA Ratio | 17.86 | 16.16 | 12.25 | 11.30 | 13.98 | 20.49 |
EV/EBIT Ratio | 28.25 | 27.86 | 22.07 | 15.71 | 18.51 | 35.93 |
EV/FCF Ratio | 59.46 | 35.82 | 33.24 | 44.43 | 19.33 | 81.28 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.03 | 0.03 | 0.05 | 0.00 | 0 |
Debt / EBITDA Ratio | 0.42 | 0.31 | 0.33 | 0.34 | 0.03 | 0.00 |
Debt / FCF Ratio | 1.38 | 0.70 | 0.91 | 1.35 | 0.04 | 0.02 |
Net Debt / Equity Ratio | -0.14 | -0.13 | -0.15 | -0.24 | -0.21 | -0.13 |
Net Debt / EBITDA Ratio | -1.45 | -1.38 | -1.59 | -1.72 | -1.33 | -1.42 |
Net Debt / FCF Ratio | -4.79 | -3.07 | -4.32 | -6.76 | -1.84 | -5.65 |
Asset Turnover | 0.34 | 0.33 | 0.36 | 0.39 | 0.43 | 0.40 |
Inventory Turnover | 2.08 | 2.07 | 2.11 | 2.15 | 2.32 | 2.26 |
Quick Ratio | 1.69 | 1.38 | 1.70 | 1.83 | 1.50 | 1.28 |
Current Ratio | 2.47 | 2.18 | 2.18 | 2.28 | 1.86 | 1.82 |
Return on Equity (ROE) | 6.18% | 5.10% | 3.62% | 5.11% | 9.54% | 3.13% |
Return on Assets (ROA) | 3.35% | 2.77% | 2.61% | 4.88% | 6.02% | 2.74% |
Return on Invested Capital (ROIC) | 5.90% | 5.40% | 4.69% | 8.97% | 11.18% | 4.72% |
Return on Capital Employed (ROCE) | 6.10% | 5.30% | 5.00% | 9.60% | 11.80% | 5.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.24% | 3.19% | 2.77% | 2.84% | 4.00% | 1.52% |
FCF Yield | 1.56% | 2.62% | 2.57% | 1.91% | 4.92% | 1.17% |
Dividend Yield | 0.62% | 0.80% | 0.85% | 1.03% | - | - |
Payout Ratio | 20.88% | 21.77% | 49.27% | 0.59% | 0.05% | 0.49% |
Buyback Yield / Dilution | -0.00% | 0.03% | 2.00% | -0.48% | -3.60% | 2.75% |
Total Shareholder Return | 0.66% | 0.83% | 2.85% | 0.55% | -3.60% | 2.75% |